The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses
Author Information
Author(s): Thaci Bart, Ulasov Ilya V., Wainwright Derek A., Lesniak Maciej S.
Primary Institution: The Brain Tumor Center, The University of Chicago Pritzker School of Medicine
Hypothesis
How do adenoviral vector modifications alter the innate immune response?
Conclusion
Adenoviral vector modifications can decrease immune system activation and increase the chance for immune escape.
Supporting Evidence
- Adenoviruses are the most commonly used vectors for gene therapy.
- Despite their safety profile, the efficacy of adenoviruses in gene therapy is poor due to immune responses.
- Modifications to adenoviral vectors can reduce immune activation and improve therapeutic outcomes.
Takeaway
Adenoviruses are used in gene therapy, but the body's immune response can make them less effective. By changing the virus, we can help it work better.
Methodology
This review discusses the interactions between adenoviruses and the innate immune system, focusing on the immune response pathways activated by adenoviral vectors.
Limitations
The complexity of the immune response and variability in human responses to adenoviral vectors are significant challenges.
Want to read the original?
Access the complete publication on the publisher's website